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Introduction: We assessed the relationship between the plasma
concentration of gefitinib and its efficacy in Japanese patients with
advanced non-small cell lung cancer (NSCLC).
Methods: Plasma trough levels of gefitinib were measured on days
3 (D3) and 8 (D8) by high-performance liquid chromatography in 44
patients with advanced NSCLC treated with 250 mg gefitinib daily.
Eligibility criteria included performance status 3, age  80 years,
and stages IIIB–IV cancer. Epidermal growth factor receptor mu-
tations in 23 patients were analyzed retrospectively.
Results: The median plasma gefitinib values were 662 ng/ml on D3
and 1064 ng/ml on D8, and the D8/D3 ratio was 1.587. The median
progression-free survival (PFS) was 71 days, and the median overall
survival was 224 days. Adenocarcinoma, never smoking, and high
D8/D3 ratio were associated with better PFS. Multivariate analysis
showed that PFS was associated with never smoking and high
D8/D3 ratio. Never-smokers with a high D8/D3 ratio showed the
best PFS. Overall survival was not associated with the D8/D3 ratio.
Epidermal growth factor receptor mutation analysis of 23 patients
showed that 15 patients had exon 19 deletion and/or exon 21
point mutation. Median PFS was similar between mutation-
positive and mutation-negative individuals in the high D8/D3
group, whereas mutation-negative individuals in the low D8/D3
group showed the worst median PFS.
Conclusions: A high D8/D3 ratio was independently associated
with better PFS in patients with NSCLC treated with gefitinib. Our
findings suggest that the pharmacokinetics of gefitinib may be
involved in its antitumor activity.
Key Words: Non-small cell lung cancer, Gefitinib, Chemotherapy,
Pharmacokinetics, EGFR mutation.
(J Thorac Oncol. 2010;5: 1404–1409)
Gefitinib (Iressa; AstraZeneca, UK) was the first oralepidermal growth factor receptor (EGFR) tyrosine ki-
nase inhibitor to become available in clinical practice. Al-
though modest response rates were observed in several clin-
ical trials, these trials failed to demonstrate significant
survival improvement in patients with advanced non-small
cell lung cancer (NSCLC) treated with gefitinib alone after
the failure of at least one prior chemotherapy regimen.1
However, because Asian patients and those who never
smoked derived benefits from gefitinib treatment in a sub-
group analysis,2,3 gefitinib is currently used mainly in patients
with refractory NSCLC in Japan who have never smoked.
Recently, several reports have shown that mutations in
exons 18 through 21 of the EGFR tyrosine kinase domain
were significantly associated with the clinical effects of
gefitinib.4–6 These findings have been evaluated in some
prospective clinical trials and seem to be confirmed in se-
lected patients.7
However, few studies have reported on the relationship
between the effects of gefitinib and its pharmacokinetic
parameters, although some phase I trials have suggested that
there may be a relationship between gefitinib plasma concen-
tration and skin and gastrointestinal toxicities.8,9 Thus, we
planned a prospective study to evaluate the relationship
between plasma concentration and clinical outcomes of ge-
fitinib in Japanese patients with advanced NSCLC.
In this trial, we decided to measure the plasma trough
level of gefitinib on the mornings of days 3 (D3) and 8 (D8)
to evaluate the early and late availabilities of gefitinib, re-
spectively. Steady-state plasma concentrations were achieved
in most patients 10 days from the start of treatment.8
However, a few patients showed disease progression within
10 days from the start of treatment. We were unable to assess
these patients, so we decided to evaluate the late plasma
concentration on the morning of D8. In addition, a detailed
pharmacokinetic study is invasive to the patients, and surro-
gate parameters using few blood samplings are favorable in
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the usual clinical setting. Considering these factors, we tried
to evaluate whether the early and late plasma trough levels of
gefitinib might be useful for predicting the efficacy and
toxicities of gefitinib.
PATIENTS AND METHODS
Eligibility Criteria
Eligibility criteria were as follows: histologically con-
firmed stage IIIA or IV NSCLC; age  80 years; and Eastern
Cooperative Oncology Group performance status (PS) 0 to 3.
The major exclusion criteria were as follows: interstitial
pneumonia or pulmonary fibrosis; active concomitant or re-
current history of any malignancy; pregnant or lactating
women; or other serious medical conditions. Prior radiation
therapy and chemotherapy were to be completed at least 4
weeks before enrollment. Signed informed consent was ob-
tained from each patient before treatment. The protocol and
informed consent procedures were reviewed and approved by
the ethics committee of each institute.
Patients underwent the following pretreatment evalua-
tions: a computed tomography scan of the chest and upper
abdomen was performed within 2 weeks before the start of
treatment; bone scintigraphy, computed tomography scan, or
magnetic resonance imaging of the brain was performed
within 2 weeks before the start of treatment at the treating
physician’s discretion; and a medical history, physical exam-
ination, assessment of Eastern Cooperative Oncology Group
PS, complete blood cell counts, blood chemistry studies, and
blood gas analysis were completed within 7 days before the
start of treatment.
Treatment and Blood Sampling
All patients were treated once daily with 250 mg
gefitinib. The dose of gefitinib was not modified during the
treatment period. The treatment was continued until disease
progression was seen, unacceptable toxicity became apparent,
or the patient refused to continue receiving treatment. Com-
plete blood cell counts and blood chemistry studies were done
on days 3, 8, 15, and 28 from the start of treatment. Chest
radiography was done on days 15 and 29. A computed
tomography scan of the chest was done on day 29. We
repeated chest radiography and/or computed tomography, a
complete blood count, and blood chemistry studies at least
once a month after day 29 from the start of treatment until the
treatment was over. In addition, adequate surveillance such as
computed tomography, magnetic resonance imaging, and
bone scintigraphy was performed immediately if the treating
physician suspected disease progression.
We obtained blood samples at baseline (day 0) and just
before the administration of gefitinib on the mornings of D3
(just before the third administration) and D8 (just before the
eighth administration) in heparinized tubes. Plasma was iso-
lated by centrifugation at 3000g at 4°C for 5 minutes within
1 hour of collection and stored at80°C. Then, samples were
deproteinized using an equal volume of acetonitrile and
centrifuged at 15,000g at 4°C for 5 minutes. The plasma
samples were stable for at least 6 months at 20°C.
Measurement of Plasma Trough Levels
of Gefitinib
The plasma trough levels of gefitinib were measured by
the high-performance liquid chromatography (HPLC) method
reported by Uesugi et al.10 The HPLC system consisted of a
JASCO PU-1580 pump, a JASCO 870-UV UV/vis detector
(JASCO Inc., Tokyo, Japan), and a Shimadzu C-R4A inte-
grator (Shimadzu, Kyoto, Japan). Isocratic elutions were
performed using an Inertsil ODS-3 column (5 m, 4.6 mm
I.D.  150 mm; GL Sciences Inc., Tokyo, Japan). The
ultraviolet detection wavelength was 254 nm. The mobile
phase consisted of 0.1 M triethylamine-H3PO4 (pH 8.0)-
acetonitrile-tetrahydrofuran (60:40:2, v/v/v). The flow rate
was 1.0 ml/min, and all separations were carried out at room
temperature (23–25°C). To validate our HPLC method (now
in preparation for submission), we used standard solutions of
gefitinib and examined reproducibilities for the gefitinib so-
lutions within a day (intraday) and between days (interday).
Each coefficient of variation (C.V.) of the peak areas was
7%. Regarding the intraday reproducibilities, the accuracy
of the method, which was expressed by the bias, varied
between 2.9 and 2.7%. Regarding the interday reproduc-
ibilities, the accuracy of the method varied between3.4 and
1.4%.
Evaluation
The response was evaluated according to the RECIST.11
Toxicities were assessed according to the United
States National Cancer Institute Common Toxicity Crite-
ria, version 2.12
Statistical Analysis
The primary end point of this study was progression-
free survival (PFS), which was defined as the time from the
date of beginning treatment to the date of disease progression
or death. Secondary endpoints were overall survival (OS) and
tumor response. Survival was calculated by the Kaplan-Meier
method and differences between groups were analyzed by the
log-rank test. Univariate and stepwise multivariate Cox pro-
portional hazard models were further used to assess the
contribution of each variable to survival. Spearman correla-
tion coefficients were computed to assess the relation be-
tween the ratios of the median trough levels on the mornings
of D8 and D3 and PFS. A two-tailed p 0.05 was considered
to indicate significance. All analyses were performed using
SPSS statistical software (SPSS version 11.0 for Macintosh;
SPSS Inc., Chicago, IL).
Genetic Analyses of EGFR
After additional approval for EGFR mutation analysis
by the Committee for Ethical Issues in cooperation with the
institutional review board of each institution, written in-
formed consent was obtained from each patient. Paraffin-
embedded specimens were laser capture microdissected, and
genomic DNA was extracted from the cancer cells using
DEXPAT reagent (Takara Bio Inc., Shiga, Japan) according
to the manufacturer’s protocol. Subsequently, the hot-spot
mutations in EGFR, which were the deletion in exon 19 and
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the point mutation of L858R in exon 21, were analyzed by
mutant-enriched polymerase chain reaction to increase the
sensitivity of these mutations.13,14
RESULTS
Patient Characteristics
From February 2003 to June 2004, 50 patients were
enrolled in the study. Of these 50 patients, six could not be
assessed: four were lost to sampling failure, one refused to
start treatment, and one showed progressive disease and
stopped treatment before day 7. There were no blood samples
from these patients; thus, we had to exclude them from the
analysis (modified intent-to-treat). Table 1 lists the baseline
characteristics of the 44 patients who were assessed. Their
median age was 65 years (range, 47–76 years). About two-
thirds were men with NSCLC of PS 0 or 1. The median body
surface area was 1.489 m2 (range, 1.281–1.826 m2). Smoking
patients included current and former smokers and approxi-
mately half of the patients smoked (52.3%). Only four pa-
tients did not have adenocarcinomas. Only two patients had
no prior chemotherapy, and 12 patients received 2 kinds of
chemotherapy before gefitinib.
Treatment Delivery
The median treatment duration was 55 days (range,
7–1008 days). Treatment was stopped in 16 patients: one
refused further treatment, nine showed drug-related toxicities,
one had grade 3 diarrhea, and five had grades 2 to 4 pneu-
monitis.
Toxicities
According to criteria in the United States National
Cancer Institute Common Toxicity Criteria version 2,
grade 3 or 4 drug-related toxicities were observed in eight
patients. Grade 3 or 4 pneumonitis or pneumonia occurred
in five patients; four of these cases occurred within 4
weeks from the start of treatment. Wound infection (n 
1), ileitis (n  1), and diarrhea (n  1) were easily
managed. These drug-related toxicities were not related to
plasma concentrations (data not shown). There was no
treatment-related death.
Clinical Outcomes and Plasma Concentrations
Eight patients responded to gefitinib, 15 showed stable
disease, and 16 showed progressive disease within 6 weeks
from the start of treatment. Five patients did not have mea-
surable lesions. The median PFS was 71 days (95% confi-
dence interval [CI], 0–191 days), and 1-year PFS was 15.1%
(95% CI, 5.2–26.7%) (Figure 1A). The median OS was 224
days (95% CI, 0–598 days), and 1-year survival was 40.9%
(95% CI, 26.4–55.4%) (Figure 1B).
FIGURE 1. Kaplan-Meier curves among all treated patients.
A, Progression-free survival. B, Overall survival. E: Censored
case.
TABLE 1. Baseline Characteristics of All Assessable Patients
Characteristics
No. of Patients
(n  44)
Age, yr
Median (range) 65 (47–76)
Sex
Men 28
Women 16
Stage
IIIB 5
IV 39
Performance status
0–1 32
2–3 12
Prior chemotherapy
0 or 1 regimen 15
2–4 regimens 29
Smoking
Never-smoker 21
Current or former smoker 23
Histopathology
Adenocarcinoma 40
Nonadenocarcinoma 4
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The median trough levels were 662 ng/ml (range,
115–2012 ng/ml) on the morning of day 3 and 1064 ng/ml
(range, 126–2926 ng/ml) on the morning of day 8. The
median D8/D3 ratio was 1.587 (range, 0.758–6.094). Table 2
shows the results of univariate analysis of PFS. Pathologic
subtype, smoking status, and D8/D3 ratio were significant
(for pathologic subtype, p  0.0207, hazard ratio [HR] 
0.267, 95% CI, 0.087–0.817; for smoking status, p 0.0494,
HR 0.543, 95% CI, 0.295–0.998; and for D8/D3 ratio, p
0.0158, HR  0.452, 95% CI, 0.237–0.862), although the
plasma trough levels of gefitinib on D3 and D8 were not
significant factors for PFS (D3, p  0.2549 and D8, p 
0.6424). PFS curves were stratified by histologic subtype,
smoking status, and D8/D3 ratio. We defined a high D8/D3
ratio as any ratio above the median value. The adenocarci-
noma, never-smoker, and high D8/D3 ratio groups showed
better PFS outcomes (adenocarcinoma, p  0.0116; never-
smoker, p  0.0447; and high D8/D3 ratio, p  0.0129). In
the multivariate analysis of PFS using Cox’s hazard model,
the stepwise method selected two independent prognostic
factors. In the never-smoking group versus the smoking
group, HR  0. 467 and p  0.0169. In the high D8/D3 ratio
group versus the low D8/D3 ratio group, HR  0.393 and
p  0.057. Never smoking and high D8/D3 ratio were
predictors of good PFS. Figure 2A shows PFS curves strati-
fied by smoking status and D8/D3 ratio. The median PFS of
never-smokers with high D8/D3 ratio (n  9) was 336 days
and the 1-year PFS was 33.3%. This group demonstrated the
best response to treatment (p  0.0086). Never-smokers with
low D8/D3 ratio (n 12) and smokers with high D8/D3 ratio
(n  13) demonstrated similar survival curves and moderate
responses to treatment (median, 71 days and 1-year PFS,
16.7% for never-smokers with low D8/D3 ratio; median, 46
days and 1-year PFS, 15.4% for smokers with high D8/D3
ratio). Smokers with low D8/D3 ratio (n  10) demonstrated
the worst response to treatment (median, 31 days and 1-year
PFS, 0%). Spearman rank correlation showed a positive
correlation between D8/D3 ratio and PFS (r  0.445, p 
0.0035) (Figure 2B).
In contrast to PFS, the D8/D3 ratio was not significant
in OS (p  0.6315). Plasma trough levels of gefitinib on D3
and D8 were also not significant (D3, p  0.9045 and D8,
p  0.7783). In terms of OS, only pathologic subtype and
smoking status were significant (pathologic subtype, p 
0.0178 and smoking status, p  0.0019).
FIGURE 2. A, Stratified by smok-
ing status and D8/D3 ratio. B,
Scattered plots demonstrate a posi-
tive correlation between the
D8/D3 ratio and progression-free
survival. C, Progression-free survival
curves stratified by epidermal
growth factor receptor mutations
and D8/D3 ratio.
TABLE 2. Results of Univariate Analysis of Prognostic Value
to Progression-Free Survival
Factors
Hazard
Ratio
95% Confidence
Interval p
Age, 70 yr 1.462 0.752–2.841 0.9027
Sex, women 0.962 0.514–1.799 0.2629
Stage, III 1.014 0.392–2.625 0.9769
PS, 0–1 0.725 0.368–1.426 0.3510
Prior chemotherapy, 0 or 1 0.873 0.463–1.645 0.6735
Never smoking 0.543 0.295–0.998 0.0494
Histopathology, adenocarcinoma 0.267 0.087–0.817 0.0207
D3, median 1.433 0.771–2.664 0.2549
D8, median 1.158 0.623–2.151 0.6424
D8/D3, high (median) 0.452 0.237–0.862 0.0158
PS, performance status.
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EGFR Mutations and Clinical Outcomes
Using biopsy specimens, we were able to analyze the
exon 19 deletions and exon 21 point mutations in 23 of 44
patients assessed. Fifteen (65.2%) of these 23 patients had
exon 19 deletion and/or exon 21 point mutation. In the
patients with EGFR mutation, five patients had partial re-
sponse, six had stable disease, and one had progressive
disease. Three patients did not have measurable lesions. The
median plasma trough level of gefitinib in responding patients
(n 5) was 1296.3 ng/ml and the range was 1110.5 to 2614.8
ng/ml. The median plasma trough level of gefitinib in non-
responding patients (n  7) was 958.0 ng/ml and the range
was 795.3 to 1211.6 ng/ml. There was no statistical differ-
ence between these groups of patients. The median PFS of
those in the high D8/D3 ratio group (n  13) was 336 days;
that in the low D8/D3 rate group (n  10) was 38 days. The
median PFS of the mutation-positive group (n 15) was 246
days; that of the mutation-negative group (n  8) was 38
days. Figure 2C shows the PFS curves stratified by D8/D3
ratio and EGFR mutations. The median PFS of the mutation-
positive with high D8/D3 ratio group (n  9) was 336 days;
that of the mutation-positive with low D8/D3 ratio group
(n  6) was 198 days. The median PFS of the mutation-
negative with high D8/D3 ratio group (n  4) was 248 days;
that of the mutation-negative with low D8/D3 ratio group
(n  4) was 32 days.
DISCUSSION
Our results revealed that the patients with advanced
NSCLC who showed a high ratio of D8/D3 plasma trough
levels had good PFS, although the individual plasma
trough levels on D3 and D8 did not affect PFS. The plasma
trough level of gefitinib increases almost linearly, but the
slope of the graph will gradually decrease and the plasma
concentration will reach a steady-state level in most pa-
tients around day 7 from the start of treatment.8 The D8/D3
ratio is considered to be the slope of the graph of the
plasma concentration of gefitinib until steady state is
reached. This slope is affected mainly by the metabolism
of gefitinib, and the high ratio is thought to reflect low
metabolism in each patient. However, the level of plasma
concentrations was not related to PFS in a statistically
significant manner. Li et al.15 reported that gefitinib is
more susceptible to CYP3A-mediated metabolism than
erlotinib, which may contribute to the increased apparent
oral clearance and lower systemic exposures achieved by
gefitinib relative to erlotinib. In two previous phase I trials,
significant interpatient variability was observed with ge-
fitinib as well.8,16 This significant interpatient variability
might make it difficult to reveal the relationship between
the plasma concentration of gefitinib and its antitumor
activities. It might be important to evaluate the increasing
rate of the plasma concentration of gefitinib in each patient
to clarify its influence relative to its antitumor effect.
We evaluated the blood samples at only two time
points in this study. This is a very small sample size
compared with previous gefitinib pharmacological stud-
ies.4,8,9 We tried to evaluate the relationship between the
plasma concentration of gefitinib and its clinical efficacy
using minimum sampling points in this study, because we
wanted to apply the results to most patients with NSCLC
receiving gefitinib treatment in clinical practice. This sam-
pling timing is not an especially heavy burden for the
patient, so it might be useful for modifying the gefitinib
treatment cycles or dosages according to the plasma con-
centration in clinical trials.
A phase I trial reported that the dose-limiting toxicity
of gefitinib in patients with advanced NSCLC was ob-
served at doses of 1000 mg once daily and recommended
that doses be kept between 150 and 600 mg once daily,
considering the response and the adverse events.8 Pres-
ently, 250 mg gefitinib is administered orally once daily in
clinical practice because no differences were found be-
tween 250 mg once daily administration and 500 mg once
daily administration.17,18 However, considering our results,
some patients who have good clearance of gefitinib, al-
though having gefitinib-sensitive EGFR gene mutations,
may show a prolonged response to gefitinib treatment
when the dose of gefitinib is increased.
It is well known that patients who have gefitinib-
sensitive EGFR gene mutations show dramatic response to
gefitinib but may eventually have a relapse during the
several months of treatment.19,20 Recently, many studies
also identified the various resistance mechanisms occur-
ring in NSCLC cells.21–23 However, it remains unclear
when and what kind of resistance will occur in each
patient. The D8/D3 ratio might be one of the factors
reflecting acquired resistance in patients with advanced
NSCLC, although we could not analyze the resistance
mechanisms that occurred in each patient in this study.
In conclusion, our findings suggested that the D8/D3
ratio of the plasma concentrations of gefitinib might be
involved in its antitumor activity. Further pharmacokinetic
study is needed to confirm the relationship between the
plasma concentration parameters of gefitinib and its anti-
tumor activity.
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